Cargando…

PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine

BACKGROUND: Trivalent inactivated flu vaccines (TIV) are currently the best means to prevent influenza infections. However, the protection provided by TIV is partial (about 50%) and it is needed to improve the efficacy of protection. Since the respiratory tract is the main site of influenza replicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rioux, Gervais, Mathieu, Claudia, Russell, Alexis, Bolduc, Marilène, Laliberté-Gagné, Marie-Eve, Savard, Pierre, Leclerc, Denis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022981/ https://www.ncbi.nlm.nih.gov/pubmed/24885884 http://dx.doi.org/10.1186/1477-3155-12-19

Ejemplares similares

Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles
por: Savard, Christian, et al.
Publicado: (2011)

Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine
por: Rioux, Gervais, et al.
Publicado: (2016)

Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity
por: Laliberté-Gagné, Marie-Eve, et al.
Publicado: (2021)

A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling
por: Thérien, Ariane, et al.
Publicado: (2017)

Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform
por: Laliberté-Gagné, Marie-Ève, et al.
Publicado: (2019)

Engineering of Papaya Mosaic Virus (PapMV) Nanoparticles through Fusion of the HA11 Peptide to Several Putative Surface-Exposed Sites
por: Rioux, Gervais, et al.
Publicado: (2012)

Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP
por: Babin, Cindy, et al.
Publicado: (2013)

MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy
por: Possamaï, David, et al.
Publicado: (2021)

A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age
por: Langley, Joanne, et al.
Publicado: (2020)

Molecular Modelling and Insilico Engineering of PapMV-CP Towards Display and Development of Capripox Viral Like Particles Based on Immunogenic P32 Envelop Protein is the Homologous of the Vaccinia-Viral H3L Gene: An Insilico Approach
por: Kumar, Burranboina Kiran, et al.
Publicado: (2020)

Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections
por: Brandi, Paola, et al.
Publicado: (2022)

2744. A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (Laboratory Code, FB-631) Co-administered with Seasonal TIV (2013–2014) to Healthy Adults ≥18–50 Years of Age
por: Langley, Joanne Marie, et al.
Publicado: (2019)

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection
por: Olivera-Ugarte, Santa-Mariela, et al.
Publicado: (2022)

A Novel M2e Based Flu Vaccine Formulation for Dogs
por: Leclerc, Denis, et al.
Publicado: (2013)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
por: Asavapiriyanont, Suvanna, et al.
Publicado: (2018)

Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine
por: Zhao, Ting, et al.
Publicado: (2021)

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults
por: Ambrose, Christopher S., et al.
Publicado: (2010)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch
por: Frolov, Vladimir G., et al.
Publicado: (2008)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Mucosal bacterial immunotherapy with MV130 highly reduces the need of tonsillectomy in adults with recurrent tonsillitis
por: García González, Luis-Amando, et al.
Publicado: (2019)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Normal tissue doses from MV image‐guided radiation therapy (IGRT) using orthogonal MV and MV‐CBCT
por: Li, Yuting, et al.
Publicado: (2018)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged
por: Kannan, Senthil, et al.
Publicado: (2015)

Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia
por: McManus, Meghann, et al.
Publicado: (2013)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2018)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
por: Bianculli, Pablo Manuel, et al.
Publicado: (2022)

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
por: Silveira, Fernando, et al.
Publicado: (2023)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial
por: Schmader, Kenneth E., et al.
Publicado: (2021)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

Poly(A) polymerase (PAP) diversity in gene expression – Star-PAP vs canonical PAP
por: Laishram, Rakesh S.
Publicado: (2014)

The Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccination: A Study of Maternal-Cord Blood Pairs in Taiwan
por: Lin, Shin-Yu, et al.
Publicado: (2013)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
por: Kieninger, Dorothee, et al.
Publicado: (2013)

Complete Genome Sequence of the Pokeweed Mosaic Virus (PkMV)-New Jersey Isolate and Its Comparison to PkMV-MD and PkMV-PA
por: Di, Rong
Publicado: (2016)

Pap and Panada
por: Drake, T. G. H.
Publicado: (1931)

Cannot write session to /tmp/vufind_sessions/sess_296csc6hbv6cuu3gb6gkeiujpl